About vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.41) EPS for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.02. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.19 million. View vTv Therapeutics' Earnings History.

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Millennium Management LLC and Creative Planning. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

How do I buy vTv Therapeutics stock?

Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of vTv Therapeutics stock can currently be purchased for approximately $6.63.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $226.43 million and generates $630,000.00 in revenue each year. The biotechnology company earns $-16,350,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. vTv Therapeutics employs 51 workers across the globe.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 4170 Mendenhall Oaks Pkwy, HIGH POINT, NC 27265-8345, United States. The biotechnology company can be reached via phone at +1-336-8410300 or via email at [email protected]

MarketBeat Community Rating for vTv Therapeutics (VTVT)

MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

vTv Therapeutics (NASDAQ:VTVT) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.